1. Home
  2. VYGR vs ELTX Comparison

VYGR vs ELTX Comparison

Compare VYGR & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.95

Market Cap

236.0M

Sector

Health Care

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$11.65

Market Cap

209.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
ELTX
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.0M
209.9M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
VYGR
ELTX
Price
$3.95
$11.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$21.00
$17.00
AVG Volume (30 Days)
624.9K
98.9K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
$10,135,000.00
$2,301,000.00
Revenue This Year
$34.04
N/A
Revenue Next Year
$7.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$4.70
52 Week High
$5.55
$14.93

Technical Indicators

Market Signals
Indicator
VYGR
ELTX
Relative Strength Index (RSI) 50.43 58.89
Support Level $3.72 $10.02
Resistance Level $4.30 $12.52
Average True Range (ATR) 0.22 0.86
MACD -0.01 0.01
Stochastic Oscillator 55.45 96.81

Price Performance

Historical Comparison
VYGR
ELTX

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Share on Social Networks: